Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare
A, part 1		
A, part 2(i)		
A, part 2(ii)		
A, part 2(iii)		
B (i)		
B(ii)	**X**	
C		
D		
E		
F		**X**
G		

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: **March 29, 2011**

State Party to the Convention: **Czech Republic**

Exchange of data on research centres and laboratories [1] - # 1

1. **Name(s) of facility** [2]
   Microbiological Laboratory BSL-3

2. **Responsible public or private organization or company**
   Veterinary Research Institute

3. **Location and postal address**
   Hudcova 70, 621 32 Brno, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Ministry of Agriculture

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 3 (1 unit; total area approx. 100 m^2)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Microbiological laboratory BSL 3 is designed and provided for work with Risk Group 3 microorganisms and with large volumes or high concentrations of Risk Group 2 microorganisms that pose an increased risk of aerosol spread.

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual or equivalent

Exchange of data on research centres and laboratories [1] - # 2

1. **Name(s) of facility** [2]
   Institute of Molecular Pathology (IMP) and Centre of Advanced Studies (CAS)

2. **Responsible public or private organization or company**
   University of Defence, Faculty of Military Health Sciences (Ministry of Defence)

3. **Location and postal address**
   Třebešská 1575, 500 01 Hradec Kralové

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Projects wholly financed MoD:
   BIODEFENCE - Classification of biological agents – support of an international project „Establishment and management of a common database of B-agents - A European Laboratory Biodefence Network“
   FRANCIS – Development of new prophylaxis against *Francisella tularensis*
   SPEKTROMETRIE – proposal of undisputed identification procedure of bacterial BA through mass spectrometry and molecular biology methods and test of applicability of this proposal for environmental samples
   Medical countermeasures against WMD (medical protection against impact of WMD)
   HOREČKA – Method of viral hemorrhagic fevers' causative agents rapid detection and identification

   Project financed IGA Ministry of Health:
   Vakcíny (vaccine development)

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**

   BL 3 (1 unit, 26,5 m^2)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Cultivation of microbes aimed for proteomic studies.
   Study of BA molecular structures and study of interaction of these structures with host defence systems.
   Cultivation of microbes for *in vivo* infection intended for the study of tularemia.
   Cultivation of microbes for *in vitro* infection intended for study of microbe – host cells interactions.

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)“.
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories [1] - # 3

1. **Name(s) of facility**[2]
   Central Military Health Institute, department Těchonin

2. **Responsible public or private organization or company**
   Central Military Health Institute (Ministry of Defence)

3. **Location and postal address**
   Central Military Health Institute, department Těchonin, 561 66 Těchonin, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Fully financed by the Ministry of Defence

5. **Number of maximum containment units**[3] **within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   BSL 4 (total area 50 m^2)

6. **If no maximum containment unit, indicate highest level of protection**

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Cultivation of microbe (*Francisella tularensis*, vaccine strain LVS) for immunological studies, preparation of monoclonal antibodies and PCR probes.
   cDNA and synthetic sequences of viral hemorrhagic fevers (Marburg, Machupo, Junin, Congo-Crimean, Lassa, Ebola, Sabia)

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories [1] - # 4

1. **Name(s) of facility**[2]
   Central Military Health Institute, department Prague

2. **Responsible public or private organization or company**
   Central Military Health Institute (Ministry of Defence)

3. **Location and postal address**
   Central Military Health Institute Prague, U Vojenské nemocnice 1200, 169 02 Praha 6, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Wholly financed by the Ministry of Defence

5. **Number of maximum containment units**[3] **within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BSL 2 (two units 42 m^2; totally 84 m^2)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   cDNA and synthetic sequences of viral hemorrhagic fevers (Marburg, Machupo, Junin, Congo-Crimean, Lassa, Ebola, Sabia)
   Isolated genetic material from *Bacillus anthracis*, *Brucella melitensis*, *Clostridium botulinum*, *Francisella tularensis*, *Vibrio cholerae*, *Yersinia pestis*.

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories[1] - # 5

1. **Name(s) of facility**[2]
   Laboratory for Biological Monitoring and Protection

2. **Responsible public or private organisation or company**
   National Institute for Nuclear, Chemical and Biological Protection, Department of Biological Protection

3. **Location and postal address**
   Kamenná 71, 262 31 p. Milín

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   National Institute for Nuclear, Chemical and Biological Protection is a public research institution. It is partly financed by own resources and partly financed by state budget.

5. **Number of maximum containment units**[3] **within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   BL 4 (two units 14,2 m^2; totally 28,4 m^2)

6. **If no maximum containment unit, indicate highest level of protection**

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate are:**
   Detection of BA by methods of molecular biology, microbiological cultivation and mass spectrometry. Development, verification and evaluation of methods for detection and quantification of biological agents and toxins, and protection against them.
   This laboratory is used for emergency response assistance for bioterrorism (initial triage and investigation of suspicious packages - primary identification and culture for *Bacillus anthracis*, etc.)
   bacteria: *Bacillus anthracis, Yersinia pestis, Francisella tularensis, Brucella species, Salmonella typhi, Burkholderia mallei, Burkholderia pseudomallei, Chlamydia psitaci, Coxiella burnetii, Vibrio cholerae, Clostridium botulinum*;
   RNA viruses: Virus Marburg, Virus Ebola, Virus Hantaan, Lassa fever virus, Virus Junin, Congo-Crimean haemorrhagic fever virus, Virus Machupo
   toxins: saxitoxin, trichothecene toxins, aflatoxins, conotoxin, tetrodotoxin, microcystin.

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

Exchange of data on research centres and laboratories [1] - # 6

1. **Name(s) of facility** [2]
   Division of Infectious Diseases, Department of Infectious Diseases and Epizootology, Faculty of Veterinary Medicine

2. **Responsible public or private organization or company**
   University of Veterinary and Pharmaceutical Sciences Brno (the Ministry of Education, Youth and Sports)

3. **Location and postal address**
   Palackého 1/3, 612 42 Brno

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Ministry of Education, Youth and Sports

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 3 (total area approx. 40 m^2)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   The laboratory provides research and diagnostic services (*Chlamydophilla psittaci*, Avian influenza viruses, Newcastle disease virus)

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories [1] - # 7

1. **Name(s) of facility** [2]
   National Institute of Public Health; Centre of Epidemiology and Microbiology

2. **Responsible public or private organization or company**
   Ministry of Health of the Czech Republic

3. **Location and postal address**
   Šrobárova 48, 100 42 Praha 10, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   The reported activity is wholly financed by the Ministry of Health

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 3 [3 boxes 7,3m^2 + 7,3m^2 + 10,05 m^2] total area approx. 107 m^2

8. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Diagnostic and public health laboratory
   Isolation and identification of *Mycobacterium tuberculosis* (human specimens)
   Revival and cultivation of strains of the Czech National Collection of Type Cultures
   Cultivation of low-pathogenic strains of Avian influenza viruses
   Investigation of suspicious packages (identification and culture for *Bacillus anthracis*)

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories [1] - # 8

1. **Name(s) of facility[2]**
   Bioveta, a.s.

2. **Responsible public or private organization or company**

3. **Location and postal address**
   Komenského 212, 683 23 Ivanovice na Hané, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Fully financed by own sources

5. **Number of maximum containment units[4] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BL 3

Name of laboratory	Area (m^2)
Quality control department	88
Bacterial products production department	134
Viral vaccines production department	80
Sterile pharmaceuticals production department	130
Lyophilisation department	138
Finalisation department	94

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**

Bacteria:

production: cultivation for purposes of growing and production of the bacterial mass for further use (production of preparations, storage of the bacterial strains)
use: activation of the stored freeze dried bacterial culture and cultivation
procurement: purchasing of the needed bacterial strains from both Czech and foreign collections
keeping: storage of the bacterial strains freeze-dried
import: purchasing of the needed bacterial strains from foreign collections
export: export of bacterial vaccines containing live vaccination strains
transport: transport of bacterial vaccines containing live vaccination strains
disposal: inactivation if this is a part of the technological procedure for production of the preparation
inactivation for purposes of disposal (biological waste generated during the production process of the bacterial strains and preparations – control tests, growth properties, determination of the number of CFU etc.)

The following high risk biological agents are used for development, production and control of the veterinary immunopreparations (vaccines, diagnostics):

Bacillus anthracis
Brucella melitensis
Brucella abortus
Brucella ovis
Brucella suis
Burkholderia mallei
Burkholderia pseudomallei
Chlamydophilla psittaci
Francisella tularensis
Salmonella typhi

Viruses:
production: cultivation for purposes of growing and production of the viral antigen for further use (production of preparations, storage of the viral strains)
use: activation of the stored viral strain (frozen, freeze dried…)
procurement: purchasing of the needed viral strains from both Czech and foreign collections
keeping: storage of the viral strains freeze-dried or frozen
import: purchasing of the needed viral strains from foreign collections
export: export of the viral vaccines containing live vaccination strains
transport: transport of the viral vaccines containing live vaccination strains
disposal: inactivation this is a part of the technological procedure for production of the preparation
inactivation for purposes of disposal (biological waste generated during cultivation – control tests, growth properties, determination of the titre etc.)
The following high risk biological agents are used for development, production and control of the veterinary immunopreparations:

Rabies virus
Aujeszky's disease virus
Avian influenza virus
Swine fever virus (Hog cholera virus)
Avian Newcastle disease virus
Teschen disease virus (Porcine encephalomyelitis virus)
Swine vesicular stomatitis virus (Porcine enterovirus type 9)
Bluetongue virus

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories [1] - # 9

1. **Name(s) of facility** [2]
   State Veterinary Institute Prague

2. **Responsible public or private organization or company**
   Public organization (Ministry of Agriculture, State Veterinary Administration)

3. **Location and postal address**
   Sídlištní 136/24, 165 03 Praha 6 – Lysolaje, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Financed by the Ministry of Agriculture

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BSL 3 (3 units, total area 660,3 m^2)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Food, feed and waters chemical analysis (including mycotoxins probing).
   Diagnostic and cultivation of zoopathogenic microbes and viruses used for veterinary, food and feed control, detection of pathogenic diseases and their treatment.

   National reference laboratory for Foot and mouth disease and for vesicular diseases
   National reference laboratory for Newcastle disease and Avian influenza
   National reference laboratory for diagnostics and epizootology of tuberculosis, paratuberculosis and other mycobacteriosis
   National reference laboratory for *Salmonella* species
   National reference laboratory for resistance monitoring

---

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories [1] - # 10

1. **Name(s) of facility** [2]
   State Veterinary Institute Jihlava

2. **Responsible public or private organization or company**
   public organization (Ministry of Agriculture, State Veterinary Administration)

3. **Location and postal address**
   Rantířovská 93, 586 05 Jihlava, Czech Republic

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Partly financed by own activities, partly by the Ministry of Agriculture

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BSL 3 Lab (area approx. 130 m^2)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Diagnostic and cultivation of zoopathogenic microbes and viruses used for veterinary, food and feed control, detection of pathogenic diseases and their treatment.

   National reference laboratory for BSE and animal TSE
   National reference laboratory for Bluetongue disease
   National reference laboratory for mycotoxins and other natural toxins
   National reference laboratory for Classical swine fever and African swine fever

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Exchange of data on research centres and laboratories [1] - # 11

1. **Name(s) of facility** [2]
   Tekro, spol. s r.o.

2. **Responsible public or private organization or company**
   Tekro, spol. s r.o.

3. **Location and postal address**
   Nová Dědina, 783 91 Uničov, Czech Republic; Loc: 49°48'11.096"N, 17°7'18.867"E

4. **Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
   Fully financed by own budget

5. **Number of maximum containment units[3] within the research centre and/or laboratory, with an indication of their respective size (m^2)**
   0

6. **If no maximum containment unit, indicate highest level of protection**
   BSL 3 (27,22 m^2)

7. **Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
   Food and feed control (mycotoxins probing, antibiotic and veterinary medication probing).

1) The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
2) For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark „Declared in accordance with Form A, part 2 (iii)".
3) In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent.

Form A, part 2 (i)

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

Form A, part 2 (ii)

National biological defence research and development programme

Description

1. State the objectives and funding of the programme and summarize the principal research and development activities conducted in the programme.

   The R&D activities of the national programme include: diagnostic, detection and identification techniques, development of new prophylactic tools and risk evaluation.

2. State the total funding for the programme and its source.

   Programme of national biological defence research is fully financed by the Ministry of Defence.
   Ministry of Interior finances other type of research - security research. Security research is mainly understood as the scientific study and experimentation seeking to achieve such knowledge, technical and technological standards as the Czech Republic require to acquire, embrace, maintain and develop the specific capabilities needed to safeguard the security of the state and of its population.

3. Are aspects of this programme conducted under contract with industry, academic institutions, or in other non-defence facilities?

   Yes

4. If yes, what proportion of the total funds for the programme is expended in these contracted or other facilities?

Ministry of Defence	90 %
Contractors	10 %

5. Summarize the objectives and research areas of the programme performed by contractors and in other facilities with the funds identified under paragraph 4.

   The objectives of the contracted activities are the same as mentioned above under #1

6. Provide a diagram of the organizational structure of the programme and the reporting relationships (include individual facilities participating in the programme).



7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to the national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

Forms A, part 2 (iii) are attached

National biological defence research and development programme

Facilities

1. What is the name of the facility?
Central Military Health Institute, department Těchonin

2. Where is it located (include both address and geographical location)?
561 66 Těchonín, Loc: 50°3'36.713"N, 16°36'39.812"E

3. Floor area of laboratory areas by containment level:

BL2	423 (sqM)
BL3	50 (sqM)
BL4	50 (sqM)

Total laboratory floor area 523 (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel 19

(ii) Division of personnel:

Military	11
Civilian	8

(iii) Division of personnel by category:

Scientists	8
Engineers	0
Technicians	10
Administration and support staff	1

(iv) Represented scientific disciplines:
human medicine, molecular biology

(v) Contractor staff 5

(vi) Source of funding: Ministry of Defence

(vii) What are the funding levels for the following programme areas:

Research	100 %
Development	
Test and evaluation	

(viii) Briefly describe the publication policy of the facility:
Results are published in international and national scientific and military journals and presented in scientific meetings.

(ix) Provide a list of publicly-available papers and reports resulting from the work during the previous 12 months. (To include authors, titles and full references.)

SKLÁDAL Petr, POHANKA Miroslav, KUPSKÁ Eva, ŠAFÁŘ Bohuslav: *Biosensors for Detection of Francisella Tularensis and Diagnosis of Tularemia*. In *Petr Skládal, Miroslav Pohanka, Eva Kupská, Bohuslav Šafář*. Zagreb, Croatia: InTech, 2010. pp 115-125 (11 pages). Biosensors. ISBN 978-953-7619-99-2

POHANKA Miroslav, PAVLIŠ Oto, PIKULA Jiří, TREML František, KUČA Kamil: *Modulation of Tularemia Disease Progress by the Bisquaternary Pyridinium Oxime HI-6*. Acta Vet. Brno 2010, Vol. 79: pp. 443-448

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms* and/or toxins studied, as well as outdoor studies of biological aerosols.

Immunological studies of model microorganism (*Francisella tularensis*, vaccine strain LVS) for detection of biological agents.
Viruses: Lassa, Junin, Machupo, Ebola, Marburg, Congo-Crimean haemorrhagic fever

HOREČKA – Method of viral hemorrhagic fevers' causative agents rapid detection and identification
The main aim of our research project is design and optimisation of new rapid viral hemorrhagic fevers' (VHF) detection and identification system targeting main causative pathogens. The system will be based on two steps: primary rapid detection and identification of viral family using Real-time reverse-transcription polymerase chain reaction (RT-PCR) and secondary pointed use of the same method for causative pathogen precise species determination. Output of this project will be concept of new rapid economic VHF diagnostic technique, fitting its detection limits, difficulty and material requirements of Czech army biological defence forces.

LEPTOSPIRÓZA **–** Risk evaluation and new possibilities of detection
The aim of this four-year study is to evaluate territory of Czech Republic according to leptospirosis acquiring risk with special regard for military training areas and AOR of Czech armed forces in NATO and UN missions abroad., analyze collected data and create standard operational protocol for exercise and field operations' areas with significant risk of leptospirosis. Compare analytical efficacy of available diagnostic methods for leptospires detection. Precise and accelerate direct proof of leptospiral DNA from patients' and environmental samples and pick up the most suitable method with possibility of rapid and precise detection able to work in field, fully satisfying all the requirements of Czech armed forces.

*Including viruses and prions.

National biological defence research and development programme

Facilities

1. What is the name of the facility?
Central Military Health Institute, department Prague

2. Where is it located (include both address and geographical location)?
U Vojenské nemocnice 1200, 169 02 Praha 6;

3. Floor area of laboratory areas by containment level:

BL2	84 (sqM)
BL3	0 (sqM)
BL4	0 (sqM)

Total laboratory floor area 84 (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel 10

(ii) Division of personnel:

Military	4
Civilian	6

(iii) Division of personnel by category:

Scientists	4
Engineers	2
Technicians	
Administration and support staff	

(iv) Represented scientific disciplines:
molecular biology, mass spectrometry, microbiology, epidemiology, veterinary medicine

(v) Contractor staff 0

(vi) Source of funding: Ministry of Defence

(vii) What are the funding levels for the following programme areas:

Research	100 %
Development	
Test and evaluation	

(viii) Briefly describe the publication policy of the facility:

Results are published in international and national scientific and military journals and presented in scientific meetings.

Posters:

Neubauerova V., Pisa L., Formankova V.: *Test of biological agents DNA preparation methods*. Collection of papers 10th Sympozium on NBC Protection, FOI, Umea, Sweden, 2010, ISSN 1650-1942

Hubalek M, Macela A., Neubauerova V.: *The Tools for an Operational BIO DIM Capability*. Collection of papers 10th Sympozium on NBC Protection, FOI, Umea, Sweden, 2010, ISSN 1650-1942

Hubálek M., Dresler J., Píša L., Neubauerová V., Formánková V., Dřevínek M., Stulík J., Macela A.: *The establishement and management of a common database of B-agents - EDA project*. Collection of papers 25th Conference of Czechoslovak Society for Microbiology, ČSSM, 2010, ISBN 970-80-970477-8-8

(ix) Provide a list of publicly-available papers and reports resulting from the work during the previous 12 months. (To include authors, titles and full references.)

DRESLER J., DŘEVÍNEK M., HUBÁLEK M., PÍŠA L., STULÍK J., MACELA A.: *Development of rapid identification and typing method for highly pathogenic bacteria using MALDI-TOF*. HUPO 2010 World Congress, Human Proteome Organisation, 2010, p. 236, (ABN: 832 857 435 63)

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms* and/or toxins studied, as well as outdoor studies of biological aerosols.

HOREČKA – Method of viral hemorrhagic fevers' causative agents rapid detection and identification

The main aim of our research project is design and optimalisation of new rapid viral hemorrhagic fevers' (VHF) detection and identification system targeting main causative pathogens. The system will be based on two steps: primary rapid detection and identification of viral family using Real-time reverse-transcription polymerase chain reaction (RT-PCR) and secondary pointed use of the same method for causative pathogen precise species determination. Output of this project will be concept of new rapid economic VHF diagnostic technique, fitting its detection limits, difficulty and material requirements of Czech army biological defence forces.

LEPTOSPIRÓZA **–** Risk evaluation and new possibilities of detection

The aim of this four-year study is to evaluate territory of Czech Republic according to leptospirosis acquiring risk with special regard for military training areas and AOR of Czech armed forces in NATO and UN missions abroad., analyze collected data and create standard operational protocol for exercise and field operations' areas with significant risk of leptospirosis. Compare analytical efficacy of available diagnostic methods for leptospires detection. Precise and accelerate direct proof of leptospiral DNA from patients' and environmental samples and pick up the most suitable method with possibility of rapid and precise detection able to work in field, fully satisfying all the requirements of Czech armed forces.

BIODEFENCE – Classification of biological agents – support of an international project „Establishment and management of a common database of B-agents – A European Laboratory Biodefence Network"

The goal of the project is to gather typing data for B-agents listed in project of the European biological database by the mean of mass spectrometry (MALDI-TOF, tandem mass spectrometry) and molecular biology (real-time PCR, MLST).

SPEKTROMETRIE – Proposal of undisputed identification procedure of bacterial BA through mass spectrometry and molecular biology methods and test of applicability of this proposal for environmental samples.

*Including viruses and prions.

National biological defence research and development programme

Facilities

1. What is the name of the facility?
Institute of Molecular Pathology (IMP) and Centre of Advanced Studies (CAS)

2. Where is it located (include both address and geographical location)?
Třebešská 1575, 500 01 Hradec Králové, Czech Republic

3. Floor area of laboratory areas by containment level:

BL2	64 (sqM)
BL3	26 (sqM)
BL4	0 (sqM)

Total laboratory floor area 90 (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel 27

(ii) Division of personnel:

Military	3
Civilian	24

(iii) Division of personnel by category:

Scientists	20
Engineers	0
Technicians	5
Administration and support staff	2

(iv) Represented scientific disciplines:
molecular biology, immunology, genetics, cell biology, bioinformatics, analytical chemistry

(v) Contractor staff 5

(vi) Source of funding: Ministry of Defence

(vii) What are the funding levels for the following programme areas:

Research	100 %
Development	
Test and evaluation	

(viii) Briefly describe the publication policy of the facility:
Results are published in international and national scientific and military journals and presented in scientific meetings.

(x) Provide a list of publicly-available papers and reports resulting from the work during the previous 12 months. (To include authors, titles and full references.)

Zivna L., Krocova Z., Hartlova A.,ubelkova K., Zákova J., Rudolf E., Hrstka R., Macela A.*: Pactivation of b cell apoptotic pathways in the course of Francisella tularensis infection*. Microb Pathog, 2010, Vol. 49, No. 5, pp. 226-36

Konecna K., Hernychova L., Reichlova M., Lenco J., Klimentova J., Stulik J., Macela A., Alefantis T., Delvecchio V.G.: *Comparative proteomic profiling of culture filtrate proteins of less and highly virulent Francisella tularensis strains*. Proteomics, Vol. 10, No. 24, pp. 4501-11

Balonova L., Hernychova L., Mann B.F., Link M., Bilkova Z., Novotny M.V., Stulik L.: *Multimethodological approach to identification of glycoproteins from the proteome of Francisella tularensis, an intracellular microorganism*. J Proteome Res. 2010, Vol. 9, No. 4, 1995-2005

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms* and/or toxins studied, as well as outdoor studies of biological aerosols.

FRANCIS – Development of new prophylactic tools against *Francisella tularensis* infection

Identification of new candidate molecules of protein origin suitable for the construction of better defined live or subunit vaccines and elucidation of the process of antigen presentation of tularemic peptides as a key event for the development of new strategies to treat and prevent infection with *Francisella tularensis*.

BIODEFENCE – Classification of biological agents – support of an international project „Establishment and management of a common database of B-agents – A European Laboratory Biodefence Network“

The goal of the project is to gather typing data for B-agents listed in project of the European biological database by the mean of mass spectrometry (MALDI-TOF, tandem mass spectrometry) and molecular biology (real-time PCR, MLST).

HOREČKA – Method of viral hemorrhagic fevers' causative agents rapid detection and identification

The main aim of our research project is design and optimization of new rapid viral hemorrhagic fevers' (VHF) detection and identification system targeting main causative pathogens. The system will be based on two steps: primary rapid detection and identification of viral family using Real-time reverse-transcription polymerase chain reaction (RT-PCR) and secondary pointed use of the same method for causative pathogen precise species determination. Output of this project will be concept of new rapid economic VHF diagnostic technique, fitting its detection limits, difficulty and material requirements of Czech army biological defence forces.

SPEKTROMETRIE – Proposal of undisputed identification procedure of bacterial BA through mass spectrometry and molecular biology methods and test of applicability of this proposal for environmental samples.

*Including viruses and prions.

National biological defence research and development programme

Facilities

1. What is the name of the facility?
Laboratory for biological monitoring and protection

2. Where is it located (include both address and geographical location)?
Kamenná 71, 262 31 p. Milín, Loc:

3. Floor area of laboratory areas by containment level:
BL2 100,5 (sqM)
BL3 69,3 (sqM)
BL4 28,4 (sqM)

Total laboratory floor area 198,2 (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel 8

(ii) Division of personnel:
Military 0
Civilian 8

(iii) Division of personnel by category:
Scientists 6
Engineers 1
Technicians 1
Administration and support staff 0

(iv) Represented scientific disciplines:
molecular biology, microbiology, virology, epidemiology and epizootology, analytical chemistry, proteomics

(v) Contractor staff 0

(vi) Source of funding: Ministry of Defence

(vii) What are the funding levels for the following programme areas:
Research 100 %
Development
Test and evaluation

(viii) Briefly describe the publication policy of the facility:
Results are published in international and national scientific and military journals and presented in scientific meetings.

(ix) Provide a list of publicly-available papers and reports resulting from the work during the previous 12 months. (To include authors, titles and full references.)

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms* and/or toxins studied, as well as outdoor studies of biological aerosols.

BIODEFENCE – Classification of biological agents – support of an international project „Establishment and management of a common database of B-agents – A European Laboratory Biodefence Network“

The goal of the project is to gather typing data for B-agents listed in project of the European biological database by the mean of mass spectrometry (MALDI-TOF, tandem mass spectrometry) and molecular biology (real-time PCR, MLST).

*Including viruses and prions.

Background information on outbreaks of reportable infectious diseases #1 - human

Disease	Number of cases per year				
	2006	2007	2008	2009	2010
Botulism	0	1	1	1	0
Brucelosis	0	0	1	0	1
Dengue*	9	10	11	15	17
Hantavirus pulmonary syndrome	0	0	0	1	0
Hemorrhagic fever with renal syndrome	1	3	2	5	8
Invasive meningococcal disease	77	78	86	86	60
Leptospirosis	18	24	17	32	41
Listeriosis	78	51	37	32	26
Pertusis	234	186	767	956	662
Lyme disease	4370	3559	4350	3863	3597
Q Fever	2	2	0	0	0
Salmonellosis	25102	18205	11009	10805	8623
Shigellosis	289	349	229	178	450
Tetanus	0	0	0	0	0
Tick borne encephalitis	1029	546	631	816	589
Tuberculosis[3)]	856	790	793	632	604**
Tularemia	87	54	113	65	53
Typhoid fever	9	2	4	3	4
Viral Hepatitis A	132	128	1650	1104	862
West Nile fever	0	2	0	0	0

* number of imported cases
** preliminary data

Source of data:
Epidat, Information system of notifiable diseases in the Czech Republic, Department of Biostatistics and Informatics, National Institute for Public Health, Prague,
Institute of Health Information and Statistic of the Czech Republic

Background information on outbreaks of reportable infectious diseases #2 - animal

Disease	Number of cases per year				
	2006	2007	2008	2009	2010
Bluetongue	0	1	9	4	0
BSE	3	2	0	2	0
Bovine tuberculosis	0	0	0	0	0
Bovine brucellosis	0	0	0	0	0
Classical swine fever – domestic pigs	0	0	0	0	0
Classical swine fever – wild boar	0	0	0	0	0
Enzootic bovine leucosis	0	0	1	0	0
Foot and mouth disease	0	0	0	0	0
High pathogenic avian influenza – poultry	0	5	0	0	0
High pathogenic avian influenza – wild birds	6	1	0	0	0
Low pathogenic avian influenza – poultry	0	0	0	2	0
Low pathogenic avian influenza – wild birds	0	0	0	0	0
Newcastle disease	0	1*	0	0	0
Rabies	0	0	0	0	0
Bat rabies	0	0	0	0	0

* pigeon

C. Encouragement of publication of results and promotion of use of knowledge

List of the most important publication which appeared during the year 2010:

Cinkova K., Reschova S., Kulich P., Vesely T.: *Evaluation of a polyclonal antibody for the detection and identification of ranaviruses from freshwater fish and amphibians.* Diseases of Aquatic Organisms 89, 2010, 191-198

Novotny L., Pokorova D., Reschova S., Vicenova M., Axmann R., Vesely T., Mikler J.R.: *First clinically apparent koi herpesvirus infection in the Czech Republic*. Bulletin of the European Association of Fish Pathologists 30, 2010, 85-91

Hyza P., Streit L., Gopfert E., Schwarz D., Masarik M., Jurajda M., Vasku A., Vesely J.*: Gene Expression of the Endothelin-1 in Vasospastic Flap Pedicle - an Experimental Study on a Porcine Model.* Acta Veterinaria Brno 79, 2010, 453-+

Horká, M., Kubíček, O., Chalupová, A.**,** Rosenbergová, K.**,** Kubíčková, Z., Šlais, K.: *Testing of the Influenza Virus Purification Efficiency by CIEF*. Electrophoresis 2010, 31, 1–8

Form D

Active promotion of contacts

Planed international conferences, symposia, seminars and other similar forums for exchange

a) name of the conference: 5th Central and Eastern European Proteomic Conference

arranging organization(s): Czech Proteomic Society

time 19th-22nd September 2011

place Prague, Conference centre U Hájků (Na Poříčí 42, Prague 1)

main subject(s) for the conference: Proteomes, Proteomics and Biological Systems

conditions for participation: registration fee: early registration CZK 8000,-
late registration: CZK 10000,-

point of contact for further information, registration, etc.
http://2011.czproteo.cz/ ; ceepc11@iapg.cas.cz

b) name of the conference: European Microbiology Conference and Mycoplasma Testing Conference 2011

arranging organization(s): European Compliance Academy

time 3rd – 5th May 2011

place Prague, Dorint Hotel Don Giovanni,Czech Republic

main subject(s) for the conference, etc.
The conference is intended to provide microbiological updates and "real life" experiences to support activities of pharmaceutical microbiologist.

conditions for participation: registration fee EUR 2280,-

point of contact for further information, registration, etc.
http://www.gmp-compliance.org/eca_seminar_6868.html;

c) **name of the conference:** Conference of Young Microbiologists - Tomasek Days

arranging organization(s): Department of Microbiology, Faculty of Medicine, Masaryk University in Brno and St. Anna Faculty Hospital in Brno

time 2nd–3rd June 2011

place Conference centre Komenského 2, Brno, Czech Republic

main subject(s) for the conference: general microbiology, factors of pathogenicity, epidemiology and epizootology

point of contact for further information, registration, etc.
filip.ruzicka@fnusa.cz, fruzic@med.muni.cz

d) name of the conference, etc.: Spring School on Ticks and Tick-borne Pathogens

arranging organization(s): Institute of Parasitology, Biology Centre of the ASCR, v. v. i.

time May 2011

place České Budějovice, Czech Republic

main subject(s) for the conference: Ticks and Tick-borne Pathogens

point of contact for further information, registration, etc.

Mr. Libor Grubhoffer, e-mail: liborex@paru.cas.cz

e) name of the conference, etc.: 8th International Interdisciplinary Meeting on Bioanalysis
arranging organization(s): Institute of Analytical Chemistry of the ASCR, v. v. i.
time 3rd – 4th November 2011
place Hotel Continental Brno, Czech Republic
main subject(s) for the conference: new results in bioanalytical science
conditions for participation: registration fee EUR 100,-
point of contact for further information, registration, etc.:
Mr. František Foret, e-mail: foret@iach.cz

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulation	Other measures	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other microbiological agents, or toxins, weapons, equipment and means of delivery specified in Article I	YES	YES	NO	NO
(b) Exports of micro-organisms* and toxins	YES	YES	NO	NO
(c) Imports of micro-organisms* and toxins	YES	YES	NO	NO

More information about Czech legislation available on http://www.sujb.cz/?c_id=665

* Micro-organisms pathogenic to man, animals and plants in accordance with the Convention

Declaration of vaccine production facility - #1

1. **Name of facility:**
   Baxter BioScience s.r.o.

2. **Location (mailing address):**
   Jevany-Bohumil 138, 281 63 Kostelec nad Černými lesy

3. **General description of the types of diseases covered:**

   list of products manufactured: Influenza vaccine/s (whole virion) against flu (human);
   Cell culture preparation, cultivation of influenza viruses, harvest, inactivation, purification, transfer to facility in Austria for final filling

   list of products manufactured and distributed: none

   list of products on which R&D is carried out: none

   list of products distributed: none

Declaration of vaccine production facility - # 2

1. **Name of facility:**
   Sevapharma a.s.

2. **Location (mailing address):**
   Průmyslová 1472/11, Praha 10, Hostivař, Czech Republic

3. **General description of the types of diseases covered:**
   Production of vaccines, immunomodulators, allergens and diagnostics (microbial, viral, immunochemical and other).

   viral vaccines: live vaccine against measles, mumps and rubella

   bacterial vaccines: vaccine against tetanus
   multi-component staphylococcus toxoid
   anti-staphylococcus phage lyzate for topical application

Declaration of vaccine production facility- # 3

1. **Name of facility:**
   Bioveta, a.s.

2. **Location (mailing address):**
   Komenského 212, 683 23 Ivanovice na Hané, Czech Republic

3. **General description of the types of diseases covered:**
   Manufacturer of: veterinary vaccines for use in animals
   in vitro diagnostic test kits for diagnosis of animal diseases
   diagnostic antigens
   positive diagnostic sera
   antisera and globulins for use in animals

Production of veterinary vaccines:

Bacterial

Vaccine against anthrax, Inactivated vaccine against Lyme disease, Inactivated vaccine against canine and fur animal leptospirosis, Inactivated vaccine against mycotic disease caused by Microsporum canis in dogs, Vaccine against tetanus, Live vaccine against red murrain in pigs, Inactivated vaccine against porcine erysipelas, Vaccine against enteric coli infections in suckling piglets and against porcine erysipelas, inactivated, Vaccine against enteric coli-infections of suckling piglets, Vaccine against leptospirosis in cattle and horses, Vaccine against bovine infectious keratoconjunctivitis, inactivated, Rabbit pasteurellosis vaccine inactivated, Vaccine against porcine pleuropneumonia, Pig rhinitis vaccine with dermonecrotoxical toxoid, Vaccine against salmonellosis in poultry, attenuated,
Avirulent vaccine against bovine trichophytosis, Lyophilized vaccine against bovine trichophytosis, Vaccine against horse trichophytosis, Vaccine against trichophytosis in animals with fur

Viral

Inactivated vaccine against coronary viral disease in dogs, Live vaccine against distemper, infectious hepatitis, infectious laryngotracheitis, parvovirosis and parainfluenza in dogs, Live vaccine against distemper and parvovirosis in dogs, Live vaccine against parvovirosis in dogs, Vaccine against rabies, inactivated, Vaccine against panleucopenia, calicivirus and herpesvirus infection of cats, The vaccine against feline panleukopenia, herpesviral and caliciviral infection, and rabies of cats, Inactivated vaccine against equine influenza, Vaccine against IBR inactivated, Vaccine against rabies intended for oral immunization in foxes, Live vaccine against myxomatosis, MXT, Live vaccine against infectious bronchitis in poultry, lyophilised, Live vaccine against infectious bursitis in poutry (Gumboro disease), lyophilized, Duck infectious hepatitis inactivated vaccine, Vaccine against Parvovirus Disease in Goslings, Inactivated, Live vaccine against Newcastle disease in poultry, lyophilized, Inactivated vaccine against the egg drop syndrome, Inactivated vaccine against Newcastle disease and infectious bursitis in poultry, Vaccine against porcine parvovirosis, inactivated, Vaccine against swine fever TVM-1, Vaccine against pest in rabbits, Vaccine against pest and myxomatosis in rabbits,

Combined (bacterial and viral)

Vaccine against canine distemper, infectious hepatitis, infectious laryngotracheitis, parvovirus, parainfluenza and leptospirosis in dogs and furry animals, Vaccine against

canine distemper, infectious hepatitis, infectious laryngotracheitis, parvovirus, parainfluenza, leptospirosis and rabies in dogs and furry animals, Inactivated vaccine against canine and fur animal leptospirosis and rabies, Live vaccine against red murrain and pest in pigs, Inactivated vaccine against equine influenza and tetanus, Vaccine against rota, corona and coli infections in newborn calves, inactivated, Vaccine against parvovirosis and swine erysipelas, Vaccine against rotaviral and enteral coliinfections in pigs

Diagnostic test kits

Kit for diagnostics of leucosis in cattle by immunodiffusion test, Set for serological diagnostics of brucellosis using the slow agglutination, Set for serological diagnostics of brucellosis using the quick agglutination, Set for diagnostics of brucellosis – RBT, Set for diagnostics of brucellosis using the complement bond reaction (CBR), Set for diagnostics of dourine using the complement bond reaction (CBR), Set for diagnostics of chlamydiosis using the complement bond reaction (CBR), Set for diagnostics of listeriosis by slow and quick agglutinations, Kit for diagnostics of paratuberculosis using the complement bond reaction (CBR), Set for diagnostics of pullorosis using the slow agglutination, Set for diagnostics of pullorosis using the quick agglutination, Set for diagnostics of anthrax using by precipitation method, Set for diagnostics of tularemia, Set for diagnostics of glanders using the complement bond reaction (CBR),

Declaration of vaccine production facility - # 4

1. **Name of facility:**
   Dyntec, s.r.o.

2. **Location (mailing address):**
   Pražská 328, 411 55 Terezín, Czech Republic

3. **General description of the types of diseases covered:**
   Human vaccine: per-oral vaccine against bacterial diarrhoea
   Veterinary products:
   - vaccines against *Actinobacillus pleuropneumoniae* and edema disease of pigs
   - vaccines against parvovirosis and erysipelas of pigs
   - vaccines against distemper, infectious hepatitis, infectious laryngotracheitis, parvovirosis, parainfluenza and *Leptospira icterohaemorrhagiae*, *L. grippotyphosa* and *L. sejroe* of dogs
   - vaccine for the prevention of rabies in wild carnivorous animals and stray dogs
   - vaccines against myxomatosis and viral hemorrhagic disease of rabbits

Declaration of vaccine production facility - # 5

1. **Name of facility:**
   BIOPHARM, Research Institute of Biopharmacy and Veterinary Drugs

2. **Location (mailing address):**
   Pohoři-Chotouň, 254 49 Jílové u Prahy

3. **General description of the types of diseases covered:**
   Vaccine against coccidiosis in poultry
   Antiparasitic premix for hoofed game